Skip to content
10-Q

Quarterly Report

Poseida Therapeutics, Inc.

0000950170-23-062054

← back to feed
Filed
Nov 9, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 3, 2023 95.62M sh
Long Term Debt Q3 2023 · Sep 30, 2023 $58.49M
Long Term Debt Q3 2023 · Dec 31, 2022 $58.25M
Short Term Investments Q3 2023 · Sep 30, 2023 $213.33M
Short Term Investments Q3 2023 · Dec 31, 2022 $201.12M
Cash And Equivalents Q3 2023 · Sep 30, 2023 $25.5M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $81.38M
Current Liabilities Q3 2023 · Sep 30, 2023 $76.97M
Current Liabilities Q3 2023 · Dec 31, 2022 $53.89M
Total Liabilities Q3 2023 · Sep 30, 2023 $178.59M
Total Liabilities Q3 2023 · Dec 31, 2022 $164.24M
Current Assets Q3 2023 · Sep 30, 2023 $252.66M
Current Assets Q3 2023 · Dec 31, 2022 $298.56M
Total Assets Q3 2023 · Sep 30, 2023 $302.25M
Total Assets Q3 2023 · Dec 31, 2022 $351.84M
Shares Diluted Q3 2023 · Sep 30, 2022 76.69M sh
Shares Diluted Q3 2023 · Sep 30, 2022 67.24M sh
Capex Q3 2023 · Sep 30, 2022 $3.66M
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$29.18M
Stockholders Equity Q3 2023 · Sep 30, 2022 $216.31M
Stockholders Equity Q3 2023 · Jun 30, 2022 $65.8M
Stockholders Equity Q3 2023 · Mar 31, 2022 $103.7M
Stockholders Equity Q3 2023 · Dec 31, 2021 $156.21M
Eps Diluted Q3 2023 · Sep 30, 2022 $0.92
Eps Diluted Q3 2023 · Sep 30, 2022 −$0.46
Eps Basic Q3 2023 · Sep 30, 2022 $0.92
Eps Basic Q3 2023 · Sep 30, 2022 −$0.46
Sga Expense Q3 2023 · Sep 30, 2022 $9.39M
Sga Expense Q3 2023 · Sep 30, 2022 $28.17M
Rd Expense Q3 2023 · Sep 30, 2022 $35.14M
Rd Expense Q3 2023 · Sep 30, 2022 $119M
Net Income Q3 2023 · Sep 30, 2022 $70.41M
Net Income Q3 2023 · Sep 30, 2022 −$30.68M
Net Income Q3 2023 · Jun 30, 2022 −$43.04M
Net Income Q3 2023 · Mar 31, 2022 −$58.06M
Operating Income Q3 2023 · Sep 30, 2022 $71.78M
Operating Income Q3 2023 · Sep 30, 2022 −$26.73M
Revenue Q3 2023 · Sep 30, 2022 $116.31M
Revenue Q3 2023 · Sep 30, 2022 $120.44M